Importantly, we provide evidence that the oncogenic properties of SMYD3 in endometrial cancer depend on its methyltransferase activity, as demonstrated by using an enzymatically inactive SMYD3-F183A plasmid. The gene discussed is SMYD3; the disease is endometrial cancer.